Literature DB >> 21486486

Off-pump occlusion of trans-thoracic minimal invasive surgery (OPOTTMIS) on simple congenital heart diseases (ASD, VSD and PDA) attached consecutive 210 cases report: a single institute experience.

Qing-Kui Guo1, Zhi-Qian Lu, Shao-Fei Cheng, Yong Cao, Yong-Hong Zhao, Cheng Zhang, Yue-Li Zhang.   

Abstract

OBJECTIVE: This paper intends to report our experiences by using an operation of off-pump occlusion of trans-thoracic minimal invasive surgery (OPOTTMIS) on the treatment of consecutive 210 patients with simple congenital heart diseases (CHD) including atrial septal defect (ASD), ventricular septal defect (VSD) and patent ductus arteriosus (PDA).
METHODS: The retrospective clinical data of OPOTTMIS in our institute were collected and compared to other therapeutic measures adopted in the relevant literatures. After operation, all the patients received electrocardiography (ECG) and echocardiography (echo) once a month within the initial 3 months, and no less than once every 3 ~ 6 months later.
RESULTS: The successful rate of the performed OPOTTMIS operation was 99.5%, the mortality and complication incidence within 72 hours were 0.5% and 4.8%, respectively. There were no major complications during peri-operation such as cardiac rupture, infective endocarditis, strokes, haemolysis and thrombosis. The post-operation follow-up outcomes by ECG and echo checks of 3 months to 5 years showed that there were no III° AVB, no obvious Occluder migration and device broken and no moderate cardiac valve regurgitation, except 1 VSD and 1 PDA with mild residual shunts, and 2 PDA with heart expansion after operation. However, all the patients' heart functions were in class I~II according to NYH standard.
CONCLUSION: The OPOTTMIS is a safe, less complex, feasible and effective choice to selected simple CHD patients with some good advantages and favorable short-term efficacies.

Entities:  

Mesh:

Year:  2011        PMID: 21486486      PMCID: PMC3090330          DOI: 10.1186/1749-8090-6-48

Source DB:  PubMed          Journal:  J Cardiothorac Surg        ISSN: 1749-8090            Impact factor:   1.637


  36 in total

1.  Hybrid approaches to complex congenital cardiac surgery.

Authors:  V E Hjortdal; A N Redington; M R de Leval; V T Tsang
Journal:  Eur J Cardiothorac Surg       Date:  2002-12       Impact factor: 4.191

2.  Transcatheter closure of perimembranous ventricular septal defects using the new Amplatzer membranous VSD occluder: results of the U.S. phase I trial.

Authors:  Yun-Ching Fu; John Bass; Zahid Amin; Wolfgang Radtke; John P Cheatham; William E Hellenbrand; David Balzer; Qi-Ling Cao; Ziyad M Hijazi
Journal:  J Am Coll Cardiol       Date:  2006-01-17       Impact factor: 24.094

Review 3.  Pediatric interventional cardiology: the cardiologist's role and relationship with pediatric cardiothoracic surgery.

Authors:  D J Waight; Z M Hijazi
Journal:  Adv Card Surg       Date:  2001

4.  Closure of patent ductus arteriosus during open-heart surgery. Surgical experience with different techniques.

Authors:  B S Bhati; C P Nandakumaran; P Shatapathy; S John; G Cherian
Journal:  J Thorac Cardiovasc Surg       Date:  1972-05       Impact factor: 5.209

5.  Multicenter experience with perventricular device closure of muscular ventricular septal defects.

Authors:  E A Bacha; Q L Cao; M E Galantowicz; J P Cheatham; C E Fleishman; S W Weinstein; P A Becker; S L Hill; P Koenig; E Alboliras; R Abdulla; J P Starr; Z M Hijazi
Journal:  Pediatr Cardiol       Date:  2005 Mar-Apr       Impact factor: 1.655

6.  Minimally invasive atrial septal defects repair.

Authors:  R Malhotra; Y Mishra; K K Sharma; Y Mehta; N Trehan
Journal:  Indian Heart J       Date:  1999 Mar-Apr

7.  Transcatheter closure of atrial septal defects under echocardiographic guidance without X-ray: initial experiences.

Authors:  P Ewert; I Daehnert; F Berger; A Kaestner; G Krings; M Vogel; P E Lange
Journal:  Cardiol Young       Date:  1999-03       Impact factor: 1.093

8.  Totally endoscopic atrial septal defect repair with robotic assistance.

Authors:  Michael Argenziano; Mehmet C Oz; Joseph J DeRose; Robert C Ashton; James Beck; Flora Wang; W Randolph Chitwood; L Wiley Nifong; Jaina Dimitui; Eric A Rose; Craig R Smith
Journal:  Heart Surg Forum       Date:  2002       Impact factor: 0.676

9.  Transcatheter device closure of perimembranous ventricular septal defects: mid-term outcomes.

Authors:  Jian Yang; Lifang Yang; Yi Wan; Jian Zuo; Jun Zhang; Wensheng Chen; Jun Li; Lijun Sun; Shiqiang Yu; Jincheng Liu; Tao Chen; Weixun Duan; Lize Xiong; Dinghua Yi
Journal:  Eur Heart J       Date:  2010-08-27       Impact factor: 29.983

10.  Intraoperative device closure of perimembranous ventricular septal defects without cardiopulmonary bypass: preliminary results with the perventricular technique.

Authors:  Zahid Amin; David A Danford; John Lof; Kim F Duncan; Stacey Froemming
Journal:  J Thorac Cardiovasc Surg       Date:  2004-01       Impact factor: 5.209

View more
  4 in total

Review 1.  A Narrative Review of Postoperative Anticoagulation Therapy for Congenital Cardiac Disease.

Authors:  Alexander A Boucher; Julia A Heneghan; Subin Jang; Kaitlyn A Spillane; Aaron M Abarbanell; Marie E Steiner; Andrew D Meyer
Journal:  Front Surg       Date:  2022-06-14

Review 2.  Anterolateral minithoracotomy versus median sternotomy for the treatment of congenital heart defects: a meta-analysis and systematic review.

Authors:  Chao Ding; Chunmao Wang; Aiqiang Dong; Minjian Kong; Daming Jiang; Kaiyu Tao; Zhonghua Shen
Journal:  J Cardiothorac Surg       Date:  2012-05-04       Impact factor: 1.637

3.  Peratrial Device Closure of Atrial Septal Defect Under Transesophageal Echocardiographic Guidance without Fluoroscopy Compared to Conventional On-Pump Surgical Closure.

Authors:  Zhixiang Guo; Chengxin Zhang; Huan Wang; Shenglin Ge
Journal:  Braz J Cardiovasc Surg       Date:  2017 Jan-Feb

4.  Patent foramen ovale closure by using transesophageal echocardiography for cryptogenic stroke: single center experience in 132 consecutive patients.

Authors:  Yangyang Han; Xiquan Zhang; Fengwei Zhang
Journal:  J Cardiothorac Surg       Date:  2020-01-09       Impact factor: 1.637

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.